AOD-9604

AOD-9604 is a synthetic peptide consisting of 17 amino acids, representing a modified fragment of human growth hormone (hGH). Specifically, it comprises residues 176-191 from the C-terminal end of the growth hormone molecule, with an additional tyrosine amino acid attached to the N-terminus. This structural modification gave rise to its name: Advanced Obesity Drug 9604.

The peptide was developed by Metabolic Pharmaceuticals, an Australian biotechnology company, with the specific goal of isolating the fat-metabolizing properties of growth hormone from its growth-promoting and diabetogenic effects. Full-length growth hormone (191 amino acids) provides powerful metabolic effects but also stimulates IGF-1 production, affects blood glucose regulation, and promotes cellular proliferation—all effects that complicate its therapeutic use for weight management.

Researchers discovered that the C-terminal fragment of hGH appeared responsible for many of growth hormone's lipolytic (fat-burning) effects while lacking the receptor binding capabilities that trigger IGF-1 release. By synthesizing just this fragment and adding a stabilizing tyrosine residue, they created AOD-9604—a peptide that could theoretically burn fat without the concerning side effects of full growth hormone therapy.

Unlike many research peptides that never progressed beyond animal studies, AOD-9604 has a substantial body of human clinical trial data. This provides valuable information about its safety profile and biological effects in humans, even though it never achieved regulatory approval as a weight loss therapeutic. The peptide has since gained renewed interest for its potential applications in joint health and cartilage regeneration, representing an unexpected pivot from its original metabolic focus.

AOD-9604's mechanism of action differs fundamentally from full-length growth hormone, which is precisely what makes it interesting for targeted fat metabolism research. Understanding this distinction requires examining how growth hormone normally works and why the C-terminal fragment behaves differently.

The Growth Hormone Connection

Human growth hormone exerts its effects by binding to growth hormone receptors (GHR) found throughout the body, particularly concentrated in the liver. This receptor binding triggers a cascade of intracellular signaling, most notably stimulating the liver to produce Insulin-like Growth Factor 1 (IGF-1). It's IGF-1 that mediates many of growth hormone's anabolic and growth-promoting effects, while also affecting glucose metabolism and potentially stimulating unwanted cell proliferation.

The C-terminal fragment used in AOD-9604 lacks the structural features required for GHR binding. This means it cannot trigger the classical growth hormone signaling cascade or stimulate IGF-1 production. Clinical trials confirmed this: AOD-9604 administration showed no effect on IGF-1 levels, blood glucose, or insulin sensitivity.

Lipolytic Mechanism

Research suggests AOD-9604 promotes fat metabolism through several interconnected pathways:

Beta-3 Adrenergic Receptor Modulation: Studies indicate AOD-9604 may enhance signaling through beta-3 adrenergic receptors, which are predominantly expressed in adipose tissue. These receptors, when activated, stimulate lipolysis through the classic cAMP-PKA pathway, leading to hormone-sensitive lipase (HSL) activation and triglyceride breakdown.

Direct Adipocyte Effects: In vitro studies on isolated fat cells demonstrate that AOD-9604 increases lipolytic activity independent of food intake or catecholamine release. The peptide appears to directly affect adipocyte metabolism, enhancing fat oxidation while simultaneously suppressing lipogenesis.

Fat Oxidation Enhancement: Animal studies show increased fatty acid oxidation rates in AOD-9604-treated subjects without corresponding decreases in food consumption. This suggests the peptide enhances the body's preference for using fat as fuel rather than reducing overall energy intake.

Cartilage Regeneration Pathway

More recent research has revealed AOD-9604's unexpected effects on cartilage cells (chondrocytes). Studies demonstrate that the peptide stimulates proteoglycan and collagen synthesis in articular cartilage. The mechanism appears distinct from its metabolic effects, possibly involving stimulation of chondrocyte proliferation and extracellular matrix production. This dual activity—metabolic and regenerative—makes AOD-9604 unique among growth hormone-derived peptides.

AOD-9604 benefits from a more extensive clinical research history than most peptides in the biohacking community. Its journey through formal pharmaceutical development generated substantial human data, while more recent studies have explored novel applications.

Obesity Clinical Trials

Metabolic Pharmaceuticals conducted multiple human trials of AOD-9604 for obesity treatment:

Phase 1 Studies: Initial safety studies in healthy volunteers established that AOD-9604 was well-tolerated across a range of doses. Importantly, these studies confirmed the peptide's key differentiating feature: it did not affect IGF-1 levels, blood glucose, or insulin sensitivity—distinguishing it from full growth hormone.

Phase 2 Trials: Proof-of-concept studies showed encouraging results. Obese participants receiving AOD-9604 demonstrated statistically significant reductions in body fat compared to placebo groups. Particularly notable was the reduction in visceral (abdominal) fat, which is metabolically the most concerning fat depot.

Phase 2b/3 Trial: The pivotal trial enrolled 536 obese participants in a 24-week, randomized, double-blind, placebo-controlled study. While the trial showed trends toward fat reduction—particularly abdominal fat—the primary endpoint of statistically significant weight loss compared to placebo was not achieved. The company cited issues with trial design and the relatively short treatment duration as potential factors. However, the extensive safety data generated confirmed AOD-9604's favorable safety profile.

Animal Studies on Fat Metabolism

Preclinical research in obese Zucker rats and other animal models provided the foundation for human trials:

• Chronic administration reduced body fat accumulation without affecting food intake
• Enhanced fatty acid oxidation rates were observed in treated animals
• No effect on lean body mass, confirming selective action on adipose tissue
• Improved lipid profiles in some models, with reduced circulating triglycerides

Cartilage and Joint Research

Following the obesity program's discontinuation, researchers explored AOD-9604's regenerative potential:

A 2012 study in the Journal of Orthopaedic Research examined AOD-9604 in a sheep model of cartilage damage. The results showed improved cartilage regeneration compared to controls, with enhanced proteoglycan content and improved histological appearance of repaired tissue. These findings prompted further investigation into joint health applications.

In vitro studies on human chondrocytes demonstrated that AOD-9604 stimulates synthesis of key cartilage matrix components—proteoglycans and collagen. The peptide also appeared to enhance chondrocyte proliferation, suggesting potential for cartilage tissue restoration.

Oral Bioavailability Research

One of AOD-9604's notable properties is its demonstrated oral activity. Metabolic Pharmaceuticals developed sublingual lozenge formulations that achieved systemic absorption while bypassing hepatic first-pass metabolism. In 2010, AOD-9604 received FDA Generally Recognized as Safe (GRAS) status for use in food products, though this pertained to a specific calcium supplement formulation rather than therapeutic claims.

AOD-9604 dosing protocols in research settings vary considerably, reflecting its different routes of administration and evolving research focus. All dosing information derives from clinical trials and preclinical research—not approved therapeutic use.

Clinical Trial Dosing

Human clinical trials for obesity utilized the following protocols:

The higher oral doses reflect the reduced bioavailability compared to injection. Sublingual lozenges were designed to maximize absorption through the oral mucosa while minimizing gastrointestinal degradation.

Research Protocols

Current research settings often employ subcutaneous injection due to its reliable pharmacokinetics:

Reconstitution

Standard peptide reconstitution practices apply:

• Reconstitute lyophilized powder with bacteriostatic water or sterile water
• Add diluent slowly down the vial wall; do not shake or agitate
• Allow to dissolve completely before drawing doses
• Store reconstituted solution at 2-8°C and use within 21 days
• Lyophilized powder should be stored at -20°C for long-term stability

Injection Site

Subcutaneous injection sites commonly include the abdominal region (rotating around the umbilicus) or the thigh. Some protocols suggest injecting near the target fat area, though systemic distribution makes injection site selection less critical than with some other peptides.

AOD-9604 benefits from substantial human safety data generated during clinical trials. This distinguishes it from many research peptides that lack formal human studies.

Clinical Trial Safety Profile

Across multiple Phase 1, 2, and 2b/3 clinical trials involving hundreds of participants, AOD-9604 demonstrated a favorable safety profile:

Reported Side Effects

Side effects observed in clinical trials were generally mild and transient:

• Injection site reactions: Redness, mild swelling, or discomfort at injection sites—common with any peptide injection
• Headache: Occasional reports, typically mild and self-limiting
• Indigestion: Some participants reported mild gastrointestinal symptoms
• Fatigue: Transient tiredness noted in some cases

These effects generally did not require intervention and resolved on their own. The incidence was often comparable to placebo groups, suggesting some reports may not be peptide-related.

Metabolic Safety

Key safety differentiators from growth hormone include:

• No observed effect on growth hormone or IGF-1 levels
• No impact on glucose homeostasis or insulin sensitivity
• No changes in thyroid hormone levels
• No significant effects on other hormone panels

Regulatory and Doping Considerations

AOD-9604 is not approved by the FDA for any therapeutic indication. It is classified as a research chemical. The peptide is prohibited by WADA in competitive sports, regardless of its actual performance-enhancing effects. Athletes should be aware that use would constitute a doping violation.

Contraindications and Precautions

While formal contraindications have not been established due to the lack of regulatory approval, caution would be reasonable for:

• Individuals with active cancer or history of cancer (growth-promoting effects cannot be fully ruled out)
• Pregnancy and breastfeeding (no safety data available)
• Pediatric populations (not studied in children)
• Individuals with known hypersensitivity to peptide compounds